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AbstrACt
Introduction There are no evidence-based 
interventions that can be administered in hospital 
settings following a general hospital admission after a 
suicide attempt.
Aim To determine whether a safety planning intervention 
(SPI) with follow-up telephone support (SAFETEL) is 
feasible and acceptable to patients admitted to UK 
hospitals following a suicide attempt.
Methods and analysis Three-phase development and 
feasibility study with embedded process evaluation. Phase 
I comprises tailoring an SPI with telephone follow-up 
originally designed for veterans in the USA, for use in the 
UK. Phase II involves piloting the intervention with patients 
(n=30) who have been hospitalised following a suicide 
attempt. Phase III is a feasibility randomised controlled 
trial of 120 patients who have been hospitalised following 
a suicide attempt with a 6-month follow-up. Phase III 
participants will be recruited from across four National 
Health Service hospitals in Scotland and randomised 
to receive either the SPI with telephone follow-up and 
treatment as usual (n=80) or treatment as usual only 
(n=40). The primary outcomes are feasibility outcomes and 
include the acceptability of the intervention to participants 
and intervention staff, the feasibility of delivery in this 
setting, recruitment, retention and intervention adherence 
as well as the feasibility of collecting the self-harm re-
admission to hospital outcome data. Statistical analyses 
will include description of recruitment rates, intervention 
adherence/use, response rates and estimates of the 
primary outcome event rates, and intervention effect 
size (Phase III). Thematic analyses will be conducted on 
interview and focus group data.
Ethics and dissemination The East of Scotland Research 
Ethics Service (EoSRES) approved this study in March 
2017 (GN17MH101 Ref: 17/ES/0036). The study results 
will be disseminated via peer-reviewed publication and 
conference presentations. A participant summary paper 
will also be disseminated to patients, service providers and 
policy makers alongside the main publication.
trial registration number ISRCTN62181241.
IntroduCtIon 
Suicide and self-harm are major public health 
problems. According to WHO, 804 000 people 
die by suicide each year across the globe,1 with 
approximately 6000 people dying by suicide 
each year in the UK. Those with a history of 
self-harm are at a markedly increased risk of 
suicide2; indeed 16% of those who are treated 
in hospital will have self-harmed again within 
1 year and 1 in 25 patients will die by suicide 
within 5 years.3 Despite the increased risk 
of suicide, there is a lack of evidence-based 
interventions within general hospital settings 
for those who have attempted suicide specifi-
cally. Although there are challenges in deter-
mining suicidal intent and debate about 
definitions of self-harm,4 the majority of 
patients admitted to hospital following self-
harm are cases of attempted suicide.5 There-
fore, delivering effective treatment in hospital 
and by other means in the weeks following a 
strengths and limitations of this study
 ► SAFETEL will test the feasibility and acceptability of 
a safety planning intervention (SPI) with follow-up 
telephone support to patients admitted to UK hospi-
tals following a suicide attempt.
 ► We have employed a collaborative person-centred 
approach to support the development of the SPI by 
involving those with lived experience as well as ac-
ademics and clinicians.
 ► A process evaluation is embedded within the study.
 ► We have employed a mixed-methods approach (in-
terviews, questionnaires, focus groups, medical re-
cords and hospital admission data).
 ► To enhance generalisability, this study is conducted 
in four hospitals.
 o
n
 7 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025591 on 5 February 2019. Downloaded from 
2 O'Connor RC, et al. BMJ Open 2019;9:e025591. doi:10.1136/bmjopen-2018-025591
Open access 
suicide attempt represents a vitally important opportunity 
to mitigate future suicide risk.
Despite the fact that individuals who self-harm or attempt 
suicide represent a high-risk group for suicide, there is little 
research evidence about what works to reduce risk of future 
self-harm or suicide in this population.6–12 To date, there 
are no evidence-based interventions that can be admin-
istered in hospital following an emergency admission to 
reduce the risk of future suicidal behaviour in those who 
have attempted suicide. Existing interventions tend to 
be intensive and not delivered in acute settings.7 13–15 In 
general, patients in emergency department (ED) settings 
are ‘assessed and referred on’ for further care,16 although 
there is considerable variability.
This study addresses this evidence gap by seeking to 
answer the following research question; can a new, innova-
tive, theory-driven safety planning intervention (SPI) with 
follow-up telephone support (SAFETEL), originally devel-
oped for use in veterans’ hospitals in the USA, be tailored 
and made feasible for use with patients admitted to UK 
general hospitals following a suicide attempt?
the sAFEtEL intervention
SAFETEL is an innovative and theoretically driven SPI 
with follow-up telephone support which was developed 
in the USA and aims to reduce suicide attempts. The SPI 
is a collaborative emergency safety plan developed by the 
patient in collaboration with a trained practitioner. The SPI 
is then supplemented with up to five structured follow-up 
telephone calls over 4 weeks.
A cohort comparison trial of suicidal ED patients in US 
veteran’s hospitals17 found that SPI and phone follow-up 
reduced suicidal behaviours and increased treatment 
engagement in the intervention condition. Thus, the 
intervention is very promising, pointing to the potential 
positive impacts of the SAFETEL intervention. Although 
developments in the USA are encouraging, it is important 
to determine whether this intervention can be tailored to 
and is feasible and acceptable in a UK, non-veteran, ED/
acute care setting. Then, if shown to be feasible and accept-
able, it should be rigorously assessed in a future definitive 
randomised controlled trial (RCT).
In addition to the personal distress, suicide attempts and 
suicide incur high economic costs, therefore any interven-
tion that reduces these occurrences will yield considerable 
economic benefits. Each death by suicide in the UK is esti-
mated to cost in excess of £1 370 00018 and direct costs of 
self-harm range from £1500 per annum to £3524 for 6 
months.18 19 Indeed, the overall annual cost of general 
hospital management of self-harm (for England) is estimated 
to be £162 million per year.20 The SAFETEL intervention has 
the potential, therefore, to fill an important gap in service 
provision with clear clinical impact and to reduce National 
Health Service (NHS)/societal costs. Although the focus will 
be on feasibility, we will also record readmission to hospital 
following self-harm[1] (Self-harm is defined, consistent with 
the NICE guidance, as intentional self-poisoning or self-in-
jury, irrespective of type of motive or the extent of suicidal 
intent.) in the subsequent 6 months following the index 
suicide attempt to inform effect size estimates for a full trial.
Aim
To determine whether SAFETEL is feasible and accept-
able in a UK NHS context. The study has the following 
specific objectives:
1. To adapt/tailor an innovative SPI with follow-up tele-
phone support for use within UK NHS hospital settings.
2. To investigate how participants engage with the inter-
vention.
3. To assess feasibility and acceptability of the interven-
tion.
4. To investigate trial recruitment, retention and other 
trial processes including data collection.
5. To explore the barriers and facilitators to intervention 
implementation.
6. To collect data on readmission to hospital following 
self-harm in the 6 months following the index suicide 
attempt to inform the sample size required for a full 
trial.
7. To further develop and test the logic model and theo-
retical basis of the intervention (see online supplemen-
tary appendix 1 for the proposed study logic model).
8. To assess whether an effectiveness trial is warranted.
MEthods And AnALysIs
study design
This study follows the Medical Research Council (MRC) 
guidance for the development and evaluation of complex 
interventions.21 22 The SAFETEL study is a three-phase 
development and feasibility trial of an SPI with follow-up 
telephone support (figure 1) with embedded process 
evaluation.
Phase I
In consultation with key stakeholders (patients and NHS 
staff), the existing SAFETEL intervention will be adapted 
for administration within a UK NHS context.
Phase II
Piloting of the intervention with approximately 30 
patients who have been admitted to hospital following a 
suicide attempt.
Phase III
A feasibility RCT with 120 patients who have been admitted 
to hospital following a suicide attempt. Participants will 
be randomised to either the SPI with follow-up telephone 
support+treatment as usual (n=80) or treatment as usual 
only (n=40).
We are adhering to protocol V.4 dated 26 April 2018. 
Any additional changes to the protocol will be reported 
to the Study Sponsor and receive appropriate approvals, 
as required.
Patient and public involvement
One of the study co-investigators (and co-author) is a 
service user and was involved in the development of the 
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research questions, the measures used and all aspects 
of study design and dissemination. As this is a feasibility 
study, we are seeking views from patients and others with 
experience of suicidal thoughts and attempts throughout.
settings
Participants will be recruited from 4 NHS hospitals across 
two health boards in Scotland. SAFETEL will be delivered 
to intervention arm participants (in addition to treat-
ment as usual) in these hospitals. The safety planning 
component of the intervention will be conducted face-
to-face in these hospitals with telephone-based support 
sessions conducted up to 4 weeks later. The follow-up 
phone calls will typically begin when the participant has 
been discharged from hospital (see 'Follow-up telephone 
support' section for more details). Baseline data collec-
tion will also be conducted in the hospitals. Qualitative 
interviews and focus groups will be conducted at NHS 
or University of Glasgow sites, in phase III study partici-
pants will be given the option of being interviewed over 
the phone or in their own homes. Staff participating in 
this phase will be interviewed at their place of work or by 
telephone.
Figure 1 SAFETEL study flow diagram V.6. Month 1 begins 1 April 2017. NHS, National Health Service; TAU, treatment as 
usual.
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Participants
To potentially receive the SAFETEL intervention, partici-
pants are eligible for the study if they meet the following 
criteria:
Inclusion criteria
1. Are aged 18 years or over.
2. Have been admitted to hospital presenting with a self-
harm episode where there was evidence of suicidal in-
tent (ie, a suicide attempt).
3. Have been assessed by the Liaison Psychiatry team.
4. Are proficient in English so that they can provide 
informed consent and complete written records in 
English.
Exclusion criteria
1. Indicate no suicidal intent.
2. Are medically unfit for interview.
3. Are unable to provide informed consent.
4. Have a level of English that is not sufficient to com-
plete the assessment measures or SPI with follow-up 
telephone support.
5. Are participating in another psychological interven-
tion study in the hospital.
6. Do not have access to a telephone.
The researcher will conduct a further assessment of the 
participant’s eligibility in regard to presence of suicidal 
intent at the baseline assessment.
study procedures
recruitment
Phase I
Individuals with lived experience of suicide (ie, have been 
suicidal in the past) will be recruited by advertising 
via mental health organisations, websites and social 
media. Information about the study will be circulated 
at the hospital sites and clinical leads at the sites will 
be approached to be interviewed or to provide contact 
details of relevant staff to approach for interview.
Phase II
Liaison Psychiatry team staff at each hospital will be 
informed of the study and the participant inclusion 
and exclusion criteria. All team members will be asked 
to identify patients who are eligible for inclusion in the 
study (eg, present following self-harm episode where 
there was evidence of suicidal intent). The hospital staff 
will inform potential participants about the study and 
invite them to meet with the study researcher following 
their psychosocial assessment with the Liaison Psychiatry 
team. If the patient agrees, the researcher will approach 
the patient and provide them with the Participant Infor-
mation Sheet, answer any questions and give them time 
to consider taking part. If the patient agrees, informed 
consent will be taken by the researcher and by consenting 
to take part, participants will agree to the research team 
accessing their medical notes. Research staff will confirm 
that participants meet inclusion criteria. We will also 
seek consent to audio-record the SPI for the purposes of 
fidelity monitoring of intervention delivery, but participa-
tion will not be contingent on consenting to this element. 
Similarly, information on the process evaluation inter-
views will be given and consent to future contact for this 
purpose will be sought, with participation in the inter-
vention/study unaffected by opting not to consent to this 
element.
Phase III
Recruitment for phase III will be the same as per phase 
II (ie, referral following assessment by hospital Liaison 
Psychiatry teams) unless feedback from phase II suggests 
modifications. For phase III, however, participants will be 
informed that they will be randomised to receive either 
the SPI with follow-up telephone support+treatment as 
usual or treatment as usual only.
Process evaluation
Participants who consented to be contacted for this 
element of the study will be invited to participate in a 
one-to-one interview about their experiences of taking 
part. In phase II, participants will be contacted after they 
have finished the telephone support component of the 
intervention (approximately 1–2 months after baseline), 
and in phase III participants (both control and interven-
tion arms) will be contacted approximately 6 months after 
baseline and once they have completed their involvement 
with the telephone follow-up component of the study. In 
phase II, the interview will be face-to-face at an NHS or 
University of Glasgow site, and in phase III, participants 
will be given the additional options of telephone inter-
view or home visit. A process evaluation-specific Partici-
pant Information Sheet and Consent Form will be sent to 
all participants in advance of the interviews and reviewed 
at the interview to ensure it is understood and then the 
consent form will be completed. In the case of telephone 
interviews, verbal consent will be audio-recorded at the 
outset of the interview.
At phases II and III, NHS staff from the hospital sites 
and those directly involved in participants’ care (eg, 
psychiatry liaison team members) will be invited to take 
part in interviews or focus groups using the same recruit-
ment method as per phase I. The study research team 
will also be invited to participate in focus groups after the 
completion of phases II and III to discuss their experi-
ences of delivering the intervention.
randomisation and blinding (phase III only)
For phase III, participants will be randomised with a 
2:1 ratio to receive either one of two study allocations: 
(i) the SPI with follow-up telephone support+treatment 
as usual or (ii) treatment as usual only. As we are most 
interested in exploring the feasibility of the intervention, 
we randomised 2:1 to extract the maximum information 
out of the data. Following consent and completion of the 
initial study measures, participants will be randomised 
using a telephone randomisation service provided by 
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the Robertson Centre for Biostatistics (RCB), Univer-
sity of Glasgow (within the Glasgow Clinical Trials Unit). 
Neither the participant nor the researcher will know 
the allocation while initial study measures are being 
recorded. After randomisation, both the participant 
and the researcher will be unblinded to the participant’s 
allocation, which is unavoidable given the nature of the 
trial. No changes in assignment will be possible. Rando-
misation will be performed using a mixed minimisation/
randomisation method. Within each hospital site, 3 out 
of every 15 participants will be allocated at random (in 
a 2:1 ratio), and 12 will be allocated according to a mini-
misation algorithm, designed to minimise imbalance 
with respect to hospital site, gender (as indicated by their 
current health record at date of consent) and history of 
self-harm (0–1 previous episodes vs 2 or more episodes). 
Whether participants are to be allocated at random, or 
by minimisation, will be determined by a computer-gen-
erated, block randomisation schedule, to be stored in a 
secure area of the RCB network, with access restricted to 
those responsible for the maintenance of the randomisa-
tion system.
Figure 2 shows the flow of participants through phase 
III of the study.
Withdrawal, loss to follow-up and retention strategies
Participants may fall into three categories relating to 
ceasing their participation in the study, these are:
i. Lost to completion of the SPI.
ii. Lost to follow-up data collection (ie, telephone fol-
low-up calls).
iii. Withdrawn from the study.
Participants will be withdrawn from the study based on 
the following circumstances:
1. If the participant requests to be withdrawn from the 
study.
2. If it becomes known (eg, through telephone contact 
during the intervention or by other means) that the 
participant has lost capacity.(A person lacks capacity 
in relation to a matter if at the material time they are 
unable to make a decision for themselves in relation 
to the matter because of an impairment of, or a dis-
turbance in the functioning of, the mind. This impair-
ment may be permanent or temporary in nature.)
If a participant is withdrawn from the study, we will still 
use the assessment and other data collected (including 
follow-up clinical data regarding hospital readmission for 
self-harm) unless the participant explicitly states that they 
wish to have their data removed from the study.
study engagement, retention strategies and adverse events
The study will use the following retention strategies to 
support participants to continue their engagement in the 
study alongside their treatment as usual commitments. 
The first telephone follow-up calls will be attempted up 
to 72 hours following discharge from hospital, and weekly 
thereafter at a time and date agreed with the participant. 
Call slots will be flexible and pragmatic as the study time 
elapses. In the event that a participant cannot be reached 
across three calls over two calendar days, the next call 
made will be to the participant’s provided emergency 
contact to establish that the patient is safe and well. In 
the event that a follow-up call informs the research team 
directly or via a third party that the participant has been 
re-admitted to hospital for self-harm/suicide attempt 
(ie, the occurrence of an adverse event); or the call itself 
requires the study team to support the participant to seek 
help or to stay safe (ie, experiencing suicidal ideation), a 
further follow-up call will be offered. This additional call 
will act to provide adequate support to the participant and 
facilitate ongoing follow-up engagement. The researcher 
will follow the study Standard Operating Procedures to 
take appropriate action to maintain participant safety, 
which may include contacting existing care providers, 
referral to the ED or calling the emergency services. Data 
on the number, type and context of all adverse events will 
be routinely recorded in line with NHS and Good Clinical 
Practice regulations and reported to the Trial Steering 
Committee (TSC) and study senior management. The 
TSC will thereafter report to the study sponsor and gover-
nance management team as agreed in the initial stages 
of the ethical approval process. Given the nature of this 
study, we anticipate adverse events will occur.
Control and intervention groups
All participants will be invited to complete the study 
measures and to participate in the interviews for the 
process evaluation component of the study (regardless of 
the condition that they are allocated to).
Control group
Following randomisation, participants in the control 
group (ie, treatment as usual only) will be fully debriefed 
and will receive treatment as usual. Treatment as usual 
is variable but it may include referral to one of the 
following: (i) primary care; (ii) community psychiatric 
service; (iii) third sector service; (iv) specialist mental 
health service; (v) intensive home treatment; (vi) outpa-
tient services; (vii) transfer to inpatient care; (viii) other 
services follow-up (ie, crisis card, social work input) or 
(ix) no further treatment plan. Treatment as usual will be 
characterised at each site as part of the process evaluation.
Intervention group
SATETEL will either be delivered by researchers trained by 
the intervention developers (Barbara Stanley and Gregory 
Brown), or by study investigators. This training will be 
cascaded down to new team members and researchers 
who support participant recruitment (ie, Mental Health 
Research Network researchers). The SPI element of 
the intervention will be delivered in the hospital before 
the patient is discharged. Within the SPI, patients are 
supported to complete a written, personalised safety 
plan in collaboration with the researcher. The safety plan 
comprises six steps outlined below. The purpose of the 
SPI is to help patients identify warning signs indicative 
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of an approaching suicidal crisis and to develop a list of 
internal coping strategies. In addition, patients also iden-
tify individuals in their social network who could provide 
distraction or support, and professional agencies who 
patients can contact during or preceding suicidal crises to 
reduce the risk of engaging in further suicidal behaviour. 
Although the order of completion of the safety plan is 
not completely fixed, participants will be encouraged 
to work through each step. Working through each step 
entails beginning with using one's internal resources, 
through to considering external resources such as calling 
a support person or professional service if they are in 
crisis and unable to keep themselves safe. They are also 
invited to take steps to make their environment safe by 
reducing access to lethal means (eg, restricting access to 
medication).
Figure 2 SAFETEL phase III participant flow diagram V.3. SPI, safety planning intervention; TAU,  treatment as usual. 
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developing the safety plan
At the outset of the SPI collaboration, the researcher 
conducts a further risk assessment to ensure the partic-
ipant is not at imminent risk of suicide. The patient is 
offered regular breaks during the assessment to mitigate 
fatigue and anticipated distress. Indeed, participants can 
become emotionally upset during safety plan comple-
tion, which is handled sensitively by the researcher (eg, 
offering to stop, take breaks, etc). The participant is also 
supported to complete the safety plan at a pace that suits 
their needs. The researcher explores the recent suicide 
attempt as a means to explain the purpose of the safety 
plan; and how to use it to support the participant to keep 
themselves safe during a suicidal crisis. This process aims 
to improve identification of warning signs that alert the 
participant that they may be approaching a crisis; explore 
the use of distraction techniques; encourage the idea 
of seeking social or professional support and restricting 
access to lethal means. When completing each step of the 
safety plan, the researcher explores the suitability and 
likelihood of employing these strategies during a suicidal 
crisis as well as providing examples of such strategies.
Follow-up telephone support
This component of the intervention consists of five struc-
tured telephone contacts with the participant over a 
period of 4 weeks. The first contact is typically delivered 
as soon as possible after discharge from hospital following 
the index suicide attempt (between 24 and 72 hours) 
followed by 4 weekly telephone contacts. The follow-up 
telephone calls comprise three components: 1) suicide 
risk assessment and mood check; 2) review of the partic-
ipant’s safety plan, with revisions made if required and 
3) supporting treatment engagement through explora-
tion of barriers to engagement, motivational enhance-
ment, problem-solving and support. The duration of 
follow-up calls will vary but it is expected that they will last 
around 15 min on average. At the end of each follow-up 
call (apart from the final one), the participant is asked 
if they consent to another follow-up call. Follow-up tele-
phone support is discontinued after five phone calls, if 
the participant no longer wishes to be contacted or if the 
participant can no longer be contacted. The researcher 
will attempt to contact the participant up to three times 
per scheduled contact point. They will send a text or leave 
a voicemail message if the participant cannot be reached 
by telephone and if the participant has consented to this. 
The researcher may also attempt to contact the partici-
pant by letter. In the event where a participant cannot 
be reached and there is concern regarding their safety, 
the researcher may contact the participant’s emergency 
contact (recorded at the initial assessment with the partic-
ipant’s consent) or professional services involved in the 
patient’s care (eg, their general practitioner (GP)). On 
the final follow-up call, in addition to the standard proce-
dure, the participant is asked if they are still happy to be 
contacted for information regarding the process evalua-
tion element of the study.
Process evaluation measures
The process evaluation will seek to assess feasibility and 
acceptability and explore the ways in which SAFETEL 
may operate to produce outcomes. Specifically, it will 
focus on intervention fidelity, exposure, reach, context, 
recruitment, retention and contamination, as well as the 
acceptability of study procedures. Table 1 presents the 
process evaluation framework and shows the various time 
points at which data collection and analysis are intended.
Intervention fidelity checking
With participants’ consent, all SPI sessions in phases II 
and III will be audio-recorded. Fidelity of intervention 
delivery is being checked in different ways for the face-to-
face sessions and telephone sessions. For the face-to-face 
sessions, 20% of the recordings will be randomly selected 
to check fidelity against a standardised measure of fidelity 
for the SPI (SPI Rating Scale; Brown, G. K. & Stanley, 
B. Safety Plan Intervention Rating Scale). These will be 
double coded by another team member and tested using 
Cronbach’s α to test inter-rater reliability. A standardised 
checklist for the follow-up telephone support calls will be 
completed by the research team to enhance intervention 
fidelity and the results will be reported descriptively.
Qualitative interviews with study participants
We will conduct semi-structured interviews with interven-
tion participants at phase II (n=up to 10) and Phase III 
(n=up to 30). Actual numbers will depend on data satura-
tion. Participants will be purposively sampled based on a 
number of criteria (ie, gender, age, hospital site of recruit-
ment, engagement with the intervention and history of 
self-harm). Semi-structured interview topic guides will 
be used and interviews will seek to explore participants’ 
experience of the study and intervention including 
contextual factors, acceptability of study and intervention 
procedures, barriers and facilitators to engagement with 
the intervention and potential mediators of change. We 
will also seek to interview participants in the control arm 
at phase III (n=up to 10) to explore their experiences of 
their treatment as usual, potential contamination and the 
acceptability of study procedures.
Qualitative interviews/focus groups with staff
We will conduct semi-structured interviews with NHS clin-
ical staff involved in the care of patients who have been 
admitted to hospital following a suicide attempt at phase 
II (n=up to 6) and phase III (n=up to 10). The interviews 
will focus on current context, procedures and services 
available to patients, feasibility of the intervention and 
acceptability of the study and intervention procedures, 
including experienced or perceived barriers and facilita-
tors, intervention ‘fit’ within the setting and suggestions 
for improvement. In addition, we will conduct focus 
groups at phases II and III with researchers responsible 
for study recruitment, data collection and intervention 
delivery (all researchers will be included where possible). 
Focus groups will explore experiences of recruitment, 
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data collection and intervention delivery, as well as 
perception of participants’ experiences.
data on recruitment, retention and adherence
Data on the number of potential participants approached, 
who declined, were ineligible and those who consented 
and were retained will be recorded and presented in the 
Consolidated Standards of Reporting Trials diagram for the 
study. Concerning adherence to the intervention, we will 
record details of all intervention-related contacts, including 
number/length of sessions of support completed and 
contact attempts made, in order to build a comprehensive 
picture of how participants engage with the study and the 
intervention. Data on the rate of safety plan completion 
Table 1 Process evaluation framework for analysis (V.3.0, 27 June 2018)
Evaluation area Questions
Fidelity
(the degree to which the 
intervention was delivered as 
intended)
 ► What is the intervention?
 ► Was the intervention (safety plan (SP) and follow-up telephone calls) delivered as intended?
 ► Was there consistency in terms of how the intervention was delivered?
 ► What, if any, adaptations were needed to the planned intervention? And were they needed?
 ► What barriers, if any, were there to delivering the intervention in a consistent way? (SP and follow-
up telephone calls)?
Exposure
(the extent to which participants 
received and understood 
the different elements of the 
intervention and whether they 
implemented these as intended. 
Their satisfaction with the 
intervention and barriers to 
receipt and implementation were 
also considered)
 ► To what extent did participants take up all potential elements of the full programme of intervention 
(SP and five follow-up telephone calls)?
 ► To what degree did participants receive the minimum dose (SP and one follow-up phone call)?
 ► To what extent was the SP completed as intended by the participant? If it was not what were the 
reasons for that?
 ► How did participants use the safety plan they had developed? (eg, frequency of use, practicality— 
where did they keep it, did they share with others)
 ► To what extent did participants alter or amend their safety plans throughout the course of the 
intervention?
 ► What elements of the intervention did participants find helpful/unhelpful and why? What elements 
of the intervention would participants change and why?
 ► What changes, if any, did participants feel that they implemented as a result of taking part in the 
intervention?
 ► What factors were involved in ongoing engagement with the intervention?
 ► What do participants report were barriers and facilitators to developing the SP, engaging with 
telephone support and using the SP in practice?
 ► What feedback do participants have regarding feasibility and acceptability of the SP and follow-up 
telephone calls?
Reach
(the extent to which the target 
audience is reached by the 
intervention, as well as any 
‘spill over’ effects on people not 
recruited)
 ► How well does the study sample represent the population of interest?
 ► Did participants report sharing their SP with family or friends?
 ► To what extent did the intervention reach and influence people other than recruited participants?
Context
(includes information relating 
to aspects of the context in 
which the intervention was 
delivered, as well as broader 
context that both practitioner 
and client were operating within 
that may influence intervention 
effectiveness)
 ► What participant-centred contextual factors influenced engagement with the intervention (safety 
planning and follow-up calls) and use of the SP in practice?
 ► What contextual factors within participants’ day-to-day environment influenced engagement with 
the intervention (safety planning and follow-up calls) and use of the SP in practice?
 ► How did the context in which the intervention was delivered influence engagement with the 
intervention and use of the SP in practice?
 ► Was the SP useful in certain circumstances and not in others?
 ► How does the intervention fit in with what is delivered in hospital (how easy was is it to deliver in 
this setting and does it conflict with anything)?
 ► What were the particular context-related difficulties/issues that arose during the study in delivering 
the intervention?
Recruitment and retention  ► How did participants feel about being approached/recruited in hospital setting?
 ► How acceptable were study and intervention procedures to participants?
 ► What motivated study participants to agree to take part? (And what kept them engaged?)
 ► Were there any difficulties in recruitment?
 ► What is the attrition rate overall and by subgroup? That is, intervention groups and control
 ► What were the reasons for withdrawal?
Contamination  ► What are the characteristics of other groups or services people are attending or resources they are 
using—do these provide any elements of the intervention?
 ► Have participants used an SP or similar in the past?
 ► Did participants in the treatment as usual (TAU) arm investigate ‘SP’ strategy on their own?
 ► Have any of the TAU arm participants seen intervention content from other participants?
 ► How did randomisation to the TAU arm affect participants?
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and the use of safety plans between telephone contacts are 
recorded as well as the amount/and type of changes made to 
safety plans over the course of the (up to) five follow-up calls.
outcome measure feasibility
Baseline
For phases II and III, all participants will be asked to complete 
a number of measures during the initial assessment at base-
line with a trained researcher (see below). The purpose of 
collecting these will be to assess feasibility and acceptability 
of using these questionnaires in a full trial, as well as to char-
acterise the sample and explore potential moderators. We 
will also record participant demographics, information on 
treatment as usual received by participants and other rele-
vant information regarding the sample (eg, suicidal history), 
which may be considered potential moderators or mediators 
in a full trial. The schedule of baseline measure comple-
tion for phases II and III is outlined in figure 2 and detailed 
below:
 ► The Columbia Suicide Severity Rating Scale23 is a 20-item 
semi-structured brief, valid and reliable tool used to 
assess suicide risk and suicidal ideation and behav-
iours, such as previous suicide attempts as well as 
interrupted and aborted attempts and preparatory 
behaviours.
 ► The Entrapment Scale24 is a 16-item scale that examines 
feelings of entrapment and defeat using a 5-point 
Likert-type scale (ranging from 0 ‘not at all like me’ 
to 4 ‘extremely like me’). It comprises two subscales: 
internal (10 items) and external entrapment (6 
items).
 ► The Interpersonal Needs Questionnaire25 is a 12-item 
measure of perceived burdensomeness (7 items) and 
thwarted belongingness (5 items), with items rated on 
a 7-point Likert-type scale (ranging from 1 ‘not at all 
true for me’ to 7 ‘very true for me’).
 ► The ENRICHD Social Support Instrument26 is a 7-item 
measure that assesses four attributes of social support: 
emotional, instrumental, informational and appraisal 
on a 5-point Likert-type scale (ranging from 1 ‘none 
of the time’ to 5 ‘all of the time’).
 ► The following measure will also be completed at 
phase III only:
 ► The Suicide-Related Coping Scale27 (phase III only) is a 
17-item measure that assesses suicide-related coping. 
It comprises two subscales: external coping, with items 
relating to recognising and using social support and 
professional resources during suicidal crisis and lethal 
means restriction, and internal coping, with items 
pertaining to self-administered coping strategies and 
confidence in relation to coping with suicidal feel-
ings. Responses are rated on a 5-point Likert-type 
scale (ranging from 0 ‘strongly disagree’ to 4 ‘strongly 
agree’).
Follow-up telephone calls
Measures completed at follow-up calls include: (i) the 
contact inventory (ie, call duration, time between calls 
and number and means of participant contact); (ii) a 
mood and suicidal thoughts and behaviours assessment; 
(iii) a review of the safety plans and use; (iv) treatment 
engagement and (v) participant agreement to receive the 
next follow-up call.
six-month post-index data capture
Follow-up data on hospital readmissions for self-harm 
after baseline will be collected at phase II (1–2 months 
postindex suicide attempt) and phase III (6 months 
postindex suicide attempt) using NHS clinical databases 
in order to assess the viability of collecting these data in 
a full trial.
data analysis
The RCB within the University of Glasgow will provide 
statistical services in support of phase III of the trial. The 
RCB is part of the Glasgow Clinical Trials Unit, and has 
extensive experience of the design, analysis and reporting 
of clinical trials and epidemiological studies.
sample size
It is estimated that Liaison Psychiatry teams across the 
four hospitals annually see at least 3700 patients who self-
harm, and we estimate that 75% report suicidal intent.5 28 
Therefore, across 6 months of recruitment for phase III, 
there will be approximately 1388 eligible participants; 
so we are aiming to recruit 20 participants per month. 
A sample of 120 participants is sufficient to explore the 
feasibility and acceptability of the intervention and allow 
estimation of the outcome event rates for a full trial.
Quantitative data
Statistical analysis will include descriptive summaries 
of recruitment rates, attrition and retention and inter-
vention adherence. The baseline characteristics of the 
sample will be summarised. The primary outcome (read-
mission to hospital following self-harm within 6 months 
of the index suicide attempt) will be summarised by 
randomised group, and the intervention effect estimated 
using logistic regression, adjusting for minimisation 
factors (ie, hospital site, gender and history of self-harm). 
Associations between baseline characteristics and the 
primary outcome will also be assessed to explore poten-
tial moderators for a full RCT.
Qualitative data
Qualitative data from the interviews and focus groups 
conducted with study participants, NHS staff and the 
researchers who will deliver the intervention will be 
analysed via thematic analysis (phases II and III) using 
the approach by Braun and Clark.29 Thematic analysis 
is a systematic approach in which the data are initially 
coded and then collated into themes, which are then 
analysed in more detail to map out the overall data and 
examine relationships between them. Finally, themes 
are refined to produce an overall story of participants’ 
views and experiences. Data collection and analysis of 
interview data will be conducted simultaneously and the 
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analyses will inform data collection in terms of changes 
to the interview schedule (eg, adding new questions to 
probe particular areas of interest). Data collection will 
continue until data saturation is reached and variables 
coded using NVivo V.11.4.1. Due to the primary focus 
of the semi-structured interviews and focus groups, the 
identified themes are likely to be on areas of interest to 
the study evaluation (eg, recruitment, retention, accept-
ability, adherence, etc), but this method also allows unex-
pected themes to emerge and to be added to the coding 
framework. The coding framework will be discussed 
and refined with the other members of the study team. 
Twenty per cent of the interviews will be double coded 
to ensure reliability. Disagreements will be resolved by 
discussion.
Qualitative data will also be triangulated with quanti-
tative data. We will draw on qualitative and quantitative 
data to test the logic model (see online supplementary 
appendix 1) and investigate mechanisms through which 
the intervention may operate in order to further develop 
the intervention theory (phase III). All analyses will be 
specified in a detailed Qualitative Analyses Plan and 
Process Evaluation Framework.
 Progression criteria from feasibility to full trial
The feasibility and acceptability of both the trial methods 
and the SAFETEL intervention, and the potential for 
these to be developed and delivered in a full RCT are the 
key outcomes of this trial. These will be assessed using 
the progression criteria outlined in online supplementary 
appendix 2. These criteria have been developed by our 
Trial Management Group and approved by our TSC; who 
will also undertake final assessment of these following 
analyses of the findings of the study.
dAtA MAnAgEMEnt And ACCEss
The RCB (part of the Glasgow Clinical Trials Unit), within 
the University of Glasgow, will provide data management 
services in support of phase III of the trial. The RCB will 
create the database for phase III data, and provide the 
online electronic Case Record Form, as well as training 
in the use of the system. Data will be entered locally with 
data validation checks built in. RCB will also run routine 
data validation checks and alert the study management 
team to general issues or specific data queries.
All personal information will be encrypted and visible 
only to the research team; all personally identifiable 
information will be held separately from research data. 
The RCB statisticians will develop analysis programmes 
during the trial and communicate any data anomalies to 
RCB data managers. At the end of the trial, final data vali-
dation checks will be carried out prior to database lock. 
The study database will be held by RCB for the duration 
of the study and for a minimum of 5 years after study 
completion.
 data sharing
At baseline, potential participants are asked to consent to 
the following in order to participate in the study:
 ► Permission for the research team to access routinely 
collected medical data (including Community Health 
Indexnumbers) to determine what contact the partic-
ipant has had with clinical services within 5 years of 
taking part in this study, where it is relevant to their 
taking part in the research.
 ► Permission for authorised representatives of the study 
Sponsor, NHS Greater Glasgow and Clyde/NHS 
Lothian and regulatory authorities to have access to 
their personal information and research data for the 
purposes of audit.
 ► In addition, participants are given the option of 
consenting to the research team sharing their data in 
the following circumstances:
 – Anonymous storage of data in the UK data ar-
chive where other researchers can have access to 
this data only if they have scientific and ethical 
approval, and agree to preserve the confidenti-
ality of this information as set out in the study 
consent form.
 – Informing the participant’s own GP and other 
relevant mental health professionals involved in 
their care, of their participation in the study and 
sending them a copy of the participant’s safety 
plan.
serious adverse events
As discussed in 'Study engagement, retention strate-
gies and adverse events' section in detail; in the event 
of serious adverse events occurring within the study, 
standard operating procedures, robust recording and 
reporting measures to detail these occurrences will be 
employed. Any complaints made by participants or rele-
vant adverse events will be recorded and reported to TSC. 
The TSC will thereafter report to the study sponsor and 
governance management team as agreed in the initial 
stages of the approval process. The TSC will take on 
the role of Data Monitoring Committee for oversight of 
adverse events. The TSC will comprise individuals with 
extensive expertise in clinical trials, suicide prevention 
research, biostatistics and clinical practice as well as lived 
experience.
EthICs And dIssEMInAtIon
The study will be conducted in accordance with the 
recommendations for physicians involved in research 
on human participants adopted by the 18th World 
Medical Assembly, Helsinki 1964 and later revisions. 
The study results will be disseminated via peer-reviewed 
publication and conference presentations. A participant 
summary paper will also be disseminated to patients and 
policy makers who wish to receive it alongside the main 
publication.
 o
n
 7 February 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025591 on 5 February 2019. Downloaded from 
11O'Connor RC, et al. BMJ Open 2019;9:e025591. doi:10.1136/bmjopen-2018-025591
Open access
trial status
This trial is ongoing but all participants have now been 
randomised.
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